Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 11/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30285064 | 0.89 | KMT2A (0.46) | KMT2AMEN1MAPTALDH1A1KDM4E | |
| SCHEMBL30681378 | 0.86 | L3MBTL1 (0.43) | KMT2AMEN1MAPTL3MBTL1 | |
| SCHEMBL3166303 | 0.86 | L3MBTL1 (0.43) | KMT2AMEN1L3MBTL1 | |
| SCHEMBL13262985 | 0.83 | L3MBTL1 (0.41) | KMT2AMEN1MAPTL3MBTL1 | |
| SCHEMBL29651126 | 0.82 | KMT2A (0.76) | KMT2AMEN1MAPTALDH1A1KDM4E | |
| SCHEMBL1746797 | 0.82 | KMT2A (0.76) | KMT2AMEN1MAPTALDH1A1KDM4E | |
| SCHEMBL3175931 | 0.82 | ALDH1A1 (0.46) | KMT2AMEN1ALDH1A1LMNAL3MBTL1 | |
| SCHEMBL18992506 | 0.82 | NOTUM (0.43) | KMT2AMEN1MAPTALDH1A1KDM4E | |
| SCHEMBL8211914 | 0.81 | FABP4 (0.46) | L3MBTL1 | |
| SCHEMBL29992759 | 0.81 | FABP4 (0.46) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023225661-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20220144850-A1 | INDOLO HEPTAMYL OXIME ANALOGUE AS PARP INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-05-12 | — | — | US | disclosed |
| WO-2021018298-A1 | INDOLO-SEVEN-MEMBERED ACYLOXIME COMPOUNDS AS PARP INHIBITORS | 南京明德新药研发有限公司 | 2021-02-04 | — | — | WO | disclosed |
| WO-2020156577-A1 | INDOLO HEPTAMYL OXIME ANALOGUE AS PARP INHIBITOR | 正大天晴药业集团股份有限公司 | 2020-08-06 | — | — | WO | disclosed |
| US-20130210740-A1 | NEO-TRYPTOPHAN | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-08-15 | — | — | US | disclosed |
| EP-2582681-A1 | PIPERIDINYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES | Novartis AG (CH) | 2013-04-24 | — | — | EP | disclosed |
| EP-2582680-A1 | BIPHENYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES | Novartis AG (CH) | 2013-04-24 | — | — | EP | disclosed |
| US-20130090342-A1 | BIPHENYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES | NOVARTIS AG (CH) | 2013-04-11 | — | — | US | disclosed |
| US-20130090342-A1 | BIPHENYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES | NOVARTIS AG (CH) | 2013-04-11 | — | — | US | disclosed |
| US-20130090342-A1 | BIPHENYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES | NOVARTIS AG (CH) | 2013-04-11 | — | — | US | disclosed |
| US-20050272661-A1 | Neo-tryptophan | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH, A MINNESOTA CORPORATION | 2005-12-08 | — | — | US | disclosed |
| US-6921805-B2 | Neo-tryptophan | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2005-07-26 | — | — | US | disclosed |
| US-20040220108-A1 | Neo-tryptophan | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH, A MINNESOTA CORPORATION | 2004-11-04 | — | — | US | disclosed |
| US-6765099-B2 | NOVEL AMINO ACID, NEO-TRYPTOPHAN, AS WELL AS POLYPEPTIDES CONTAINING THIS NOVEL AMINO ACID SUCH AS NEUROTENSIN ANALOGS. IN ADDITION, THE INVENTION PROVIDES NEO- TRYPTOPHAN DERIVATIVES, SEROTONIN-LIKE NEO-TRYPTOPHAN DERIVATIVES AND | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2004-07-20 | — | — | US | disclosed |
| US-20030166505-A1 | Neo-tryptophan | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH, A MINNESOTA CORPORATION | 2003-09-04 | — | — | US | disclosed |
| US-20010027174-A1 | Neo-tryptophan | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH MINNESOTA CORPORATION | 2001-10-04 | — | — | US | disclosed |
| EP-1067950-A4 | NEO-TRYPTOPHAN | MAYO FOUNDATION FOR MEDICAL (US) | 2001-09-05 | — | — | EP | disclosed |
| US-6214790-B1 | POLYPEPTIDES OF NEOTRYPTOPHAN AND SYNTHESIS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2001-04-10 | — | — | US | disclosed |
| EP-1067950-A1 | NEO-TRYPTOPHAN | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2001-01-17 | — | — | EP | disclosed |
| WO-1999052539-A1 | NEO-TRYPTOPHAN | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 1999-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220108-A1 | Neo-tryptophan | NTSR1, NTSR2, TPH1 | KMT2A 3065/4885MEN1 2948/4885MAPT 2063/4885 |
| US-20030166505-A1 | Neo-tryptophan | NTSR1, NTSR2, TPH1 | KMT2A 3065/4885MEN1 2948/4885MAPT 2063/4885 |
| US-20130090342-A1 | BIPHENYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES | IGF1R, IGFBP1, IGFBP2 | KMT2A 1942/4885MEN1 747/4885MAPT 2743/4885 |
| US-20010027174-A1 | Neo-tryptophan | NTSR1, NTSR2, TPH1 | KMT2A 3065/4885MEN1 2948/4885MAPT 2063/4885 |
| US-20130210740-A1 | NEO-TRYPTOPHAN | OPRL1, GAP43, NTSR1 | KMT2A 3981/4885MEN1 3816/4885MAPT 2885/4885 |
| US-20220144850-A1 | INDOLO HEPTAMYL OXIME ANALOGUE AS PARP INHIBITOR | PARP1, PARP2, PARP3 | KMT2A 713/4885MEN1 3060/4885MAPT 465/4885 |
| US-20050272661-A1 | Neo-tryptophan | NTSR1, NTSR2, TPH1 | KMT2A 3065/4885MEN1 2948/4885MAPT 2063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.